Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance |
| |
| Authors: | Yihai Cao Weide Zhong Yan Sun |
| |
| Institution: | 1. Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, 171 77 Stockholm, Sweden;2. Department of Urology, Guangzhou First Municipal People''s Hospital, Guangzhou, China;3. Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China;1. Department of Pharmacology, School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China;2. Shandong provincial hospital affiliated to Shandong University, 250021, China;3. Sanlugen PharmaTech, Rm 506, No. 2766 Yingxiu Road, Jinan 250101, China;1. Department of Analytical Chemistry, Stockholm University, Svante Arrhenius väg 16, SE-106 91 Stockholm, Sweden;2. Institute of Environmental Medicine, Karonlinska Institutet, Box 210, SE-171 77 Stockholm, Sweden;1. Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA;2. Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA;3. Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA;4. Weill Medical College of Cornell University, New York, NY, USA;5. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA;6. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA;7. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA;8. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA;9. Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;10. Department of Epidemiology and Biostatistics, Computational Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA;1. Université de Lorraine, CNRS, CRAN, F-54000 Nancy, France;2. Université de Lorraine, Faculté de Pharmacie, Nancy, France |
| |
| Abstract: | Several antiangiogenic agents, including bevacizumab, sunitinib, and sorafenib, which mainly target the VEGF signaling system, have been approved for the treatment of human cancers. These drugs have been paired with conventional chemotherapeutic agents to treat different types of cancers, including colorectal and lung cancers; however, the patient response rate and resultant increase in overall survival time have been rather modest. The current antiangiogenic regimen is far from optimal. Improvements of therapeutic efficacy and minimization of adverse effects and drug resistance are urgent tasks that are most likely to be resolved by understanding the molecular mechanisms underlying tumor angiogenesis. The aim of this article is to discuss these clinically related issues, to highlight several recent examples of the complex interplays between tumor-produced angiogenic factors, and to propose a new paradigm for improvement of therapeutic intervention of tumor angiogenesis. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
